期刊
SEMINARS IN DIALYSIS
卷 24, 期 3, 页码 269-271出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1525-139X.2011.00938.x
关键词
-
Both the Kidney Disease Outcomes Quality Initiative (KDOQI) Guidelines and the European Best Practice Guidelines (EBPG) support the use of substantial doses of iron supplementation when iron overload cannot be confirmed. However, excessive iron reduces iron utilization and is involved in the generation of intracellular reactive oxygen species, which induce cell injury; the risk of subtle toxicity from iron excess exists. Unnecessary iron supplementation also accelerates hepcidin (HP) production. HP, via its effect on ferroportin 1 (FP1), keeps intracellular iron from being carried even if the iron storage is adequate; it also decreases iron absorption from the intestine. The Japanese Society for Dialysis Therapy Guidelines propose that aminimal amount of iron should be given to chronic kidney disease patients with anemia and only in cases of evident iron deficiency. Japanese clinicians believe that the risk/benefit ratio for iron supplementation is higher than that accepted in Western countries. When erythropoiesis-stimulating agent hyporesponsiveness exists, we should consider conditions other than iron deficiency and treat these conditions to improve iron utilization.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据